Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-05-10 00:00:00 ET · period of report 2022-05-09 · accession 0000886163-22-000060 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-05-10 | 2022-05-09 | LGND | HIGGINS JOHN L | CEO, Dir | M - OptEx | $21.92 | +8,000 | 348.6K | +2% | +$175.4K |
| D | 2022-05-10 | 2022-05-10 | LGND | HIGGINS JOHN L | CEO, Dir | S - Sale | $429,159.38 | -8,000 | 57.6K | -12% | -$3.43B |
| D | 2022-05-10 | 2022-05-09 | LGND | HIGGINS JOHN L | CEO, Dir | M - OptEx | — | 0 | — | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-09 | M | A | 8,000 | $21.92 | 348,593 | D | — | — | |
| 2 | Derivative | 0.75% Convertible Senior Notes due 2023 | 2022-05-10 | S | D | 8,000 | $429,159.38 | 57,616 | D | $248.48 · — to 2023-05-15 | 8,000 Common Stock | (F1) The notes are convertible at any time prior to the close of business on November 14, 2022 (1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of the Issuer?s common stock on such trading day is greater than 130% of the conversion price on such trading day; (2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or (3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes. |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-05-09 | M | D | — | $0.00 | — | D | $21.92 · — to 2023-02-15 | — Common Stock | (F2) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13. |